Elevated intraocular pressure (IOP) is a well-known risk factor for the development of glaucoma1,2 and the worsening of visual function measured with automated visual field (VF) testing.3 IOP is also the only glaucoma risk factor that can be modified, and treatment options including medical,1 laser,4 or surgical intervention.5 As such, IOP has served as a frequent outcome in clinical trials and is routinely tracked to assess the risk of glaucoma development and worsening in patients under clinical care. Previous longitudinal studies have demonstrated that higher mean IOP,1,5–9 maximum (peak) IOP,3,10 and SD3,10,11 of IOP are associated with higher rates of glaucoma worsening.
However, there are unresolved issues regarding the effects of IOP on VF worsening. In particular, the Early Manifest Glaucoma Trial (EMGT) has suggested that for every 1 mm Hg decrease in IOP from baseline, there is a 10% reduction in risk of VF worsening and that on further visits, the risk of VF worsening decreases by 11% to 13%12 for every additional mm Hg of mean IOP lowering. In contrast, the Advanced Glaucoma Intervention Study (AGIS) suggests that as long as the maximum IOP is consistently kept <18 mm Hg, net VF worsening is unlikely to occur.5 Thus, while EMGT suggests the lower the IOP, the better, AGIS suggests that lowering IOP to prevent maximum IOP from rising >18 mm Hg may not have a significant additional effect, as long as lowering is consistent across time. From a patient management standpoint, the resolution of this dilemma has significant implications. Less invasive medical,2 laser,13 and angle-based procedures14–16 can often achieve mean IOPs in the mid to high teens which, if found consistently across appointments, would be suggested to be safe by AGIS, whereas subconjunctival filtering surgery,17,18 with its higher rates of complications,19 is often required to achieve lower IOPs suggested to be meaningful by EMGT.
Therefore, the primary objective of this study is to clarify, in a treated clinical population, the effect of mean treated IOP on VF worsening. In this study, we specifically choose to focus on a real-world treated clinical population as much of the work studying the impact of IOP and glaucoma worsening has been done in the setting of major glaucoma clinical trials2,3,5,12 which may not be indicative of the effects of IOP control in a real-world clinical setting where the clinicians main goal is to achieve IOP control with treatment20 rather than adhere to prespecified study guidelines. While there has been some prior21–23 retrospective work that has addressed this question, sample sizes were limited. Therefore, we performed our analysis using a large database of clinical and VF data from patients treated for glaucoma at a tertiary care glaucoma practice. To achieve our primary objective of understanding the impact of mean treated IOP on VF worsening, we first analyze the effect of a 1 mm Hg change in treated IOP on VF worsening across various treated IOP ranges (ie, asking if the effect of going from a treated IOP of 24 to 23 mm Hg on VF worsening the same as going from an IOP of 14 to 13 mm Hg?). Second, we assess whether various stages of glaucoma progress at different rates at the same levels of treated IOP (ie, is an eye with advanced glaucoma more likely to progress at a treated IOP of 17 compared with an eye with mild glaucoma?). As disease progression during treatment is undesirable, our findings will help clarify the frequency and extent of treatment failures at various disease stages and IOP levels.
The study protocol was approved by the Johns Hopkins University School of Medicine Institutional Review Board (IRB) and adhered to the tenets of the Declaration of Helsinki. A waiver of consent was obtained to review VF data and obtain patient information via chart review. The study was Health Insurance Portability and Accountability Act (HIPAA) compliant.
Patients included in this study were 18 years of age or older and were evaluated at the Wilmer Eye Institute between 1998 and 2012 as previously described.24 All study participants had a glaucoma-related diagnosis (glaucoma suspect or any other form of glaucoma). We analyzed all eyes that that had 5 or more VFs which were obtained with the Humphrey Field Analyzer (HFA II, Carl Zeiss Meditec Inc., Dublin, CA) using the Swedish Interactive Threshold Algorithm (SITA) Standard test protocol and the 24-2 pattern. Patients could have either 1 or both eyes included in the analyses. We excluded VFs if the percentage of false positives was >15% for all stages of the disease and false negatives were >25% for mild/suspect disease and 50% for moderate/advanced disease.24
VF and Clinical Data Collection
VF data were retrieved for eyes meeting the inclusion criteria listed above. Mean deviation (MD) at baseline was used as the measure of disease severity: baseline MD>−6 was defined as mild/suspect disease, baseline MD >−12 and ≤−6 as moderate disease and baseline MD ≤−12 as advanced disease. Eyes with MD<−28 at baseline were not included. Due to insufficient numbers to model advanced disease in isolation (n for advanced: 162, n for moderate: 224, n for mild/suspect: 1062) we combined moderate and advanced disease into 1 subgroup. MD slope (dB change/y) was calculated for each eye using standard linear regression modeling and was used as the primary dependent variable for the study.
We performed a chart review to determine baseline demographic characteristics (age at the time of the first VF, sex, glaucoma type, glaucoma or cataract surgery before the baseline VF, interim glaucoma or cataract surgery, and baseline number of glaucoma medications). In addition, we collected treated IOP values for every visit where a VF was obtained. From these longitudinally collected treated IOP values, we calculated the mean treated IOP over follow-up for each eye. In addition, we calculated the maximum treated IOP over follow-up and the SD of treated IOP values over follow-up. To eliminate the impact of outlier treated IOP values on IOP metrics eyes with IOP values >50 mm Hg were not included. Mean, maximum, and SD of treated IOP were used as the primary independent variables in the models described below.
Modeling of Influence of IOP Characteristics and VF MD
We created scatter plots of the effects of mean, maximum, and SD of IOP over follow-up on MD slope and fit LOWESS curves to visualize the impact of differences in treated IOP parameters on MD slope, stratified by baseline disease severity. Based on these plots, we created mixed-effects linear regression models in which MD slope was the dependent variable and mean treated IOP over follow-up was the primary independent variable. Based on the appearance of the LOWESS curves demonstrating differing rates of MD slope change across different ranges of treated IOP metrics, we introduced spline terms into our models. The position of the spline knots was chosen based on the technique described by Muggeo.25 In addition, we added interaction terms to the models to capture the different relationships between MD slope and treated IOP metrics for various disease stages.
Models also included terms to account for confounders that may impact the relationship between MD slope and treated IOP including, age, sex, race, glaucoma diagnosis, presence of baseline or interim glaucoma surgery, presence of baseline or interim cataract surgery, and the number of glaucoma medications at baseline. In addition, to account for the clustering of 2 eyes from the same patient we employed a linear mixed-effects modeling approach with random intercepts. To allow for interpretability of the intercept value from the models, we centered covariates at the mean values for continuous variables and the largest group for categorical variables (female, white, phakic patient with no baseline or interim surgery). Based on the intercept and coefficient values from the models described above, we calculated the number of years it would take for the average eye in our dataset (female, white, phakic with no baseline or interim surgery) to experience a 1 dB loss VF MD at various levels of mean treated IOP over follow-up.
We also wanted to understand the impact of treated IOP measures on the likelihood of VF worsening. Therefore, we developed logistic regression models to understand the relationship between treated IOP metrics and the likelihood of a −0.5 dB per year MD change which is significantly higher than the mean rate of change in a clinical population (−0.05 dB/y).26 Models used similar parameters to linear regression models described above except spline terms were not included due to insufficient numbers beyond the spline knots. All statistical analyses were performed in R, version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).
Demographic and Ocular Characteristics
A total of 10,051 VFs and clinical examinations from 1446 eyes of 869 patients were included in the analysis. The mean age was 64 years (SD: 12.3 y), 66.2% were white, and 54.5% were female (Table 1). The majority of eyes had primary open-angle glaucoma (54.3%) and mild/suspect disease (73.2%). A minority of eyes had prior incisional glaucoma surgery or prior cataract surgery (25.7% and 21.1%, respectively). Two hundred seventy-six eyes (19.9%) underwent glaucoma surgery, and 161 eyes (11.1%) underwent cataract surgery over the course of follow-up. Eyes were on a mean of 1.3 (SD: 1.3) glaucoma medications at baseline. Mean IOP at baseline was 16.7 mm Hg (SD: 4.6 mm Hg) and decreased to 15.8 (SD: 3.6) over the study period. Each eye had on average 6.7 VFs done over the course of follow-up (SD: 1.3) with a mean follow-up time of 5.14 years (SD: 1.20 y, median: 5.39 y, range: 0.48 to 11.65 y).
TABLE 1 -
Demographic and Ocular Characteristics of Subjects Studied
| Age [mean (SD)] (y)
| Glaucoma type
| Prior glaucoma surgery
| Interim glaucoma surgery
| Baseline lens status
| Interim cataract surgery
| No. glaucoma medications [mean (SD)]
| Treated IOP data [mean (SD)]
| Baseline IOP (mm Hg)
| Mean treated IOP over follow-up (mm Hg)
| Eyes with mean treated IOP >21
| Maximum treated IOP (mm Hg)
| Mean treated SD IOP (mm Hg)
|Visual fields (N)
| No. VFs per eye [mean (SD)]
| MD at baseline (number of eyes) (dB)
| MD slope [mean (SD)] (dB/y)
IOP indicates intraocular pressure; MD, mean deviation; PACG, primary angle-closure glaucoma; PACS, primary angle-closure suspect; POAG, primary open-angle glaucoma; POAS, primary open-angle suspect; VF, visual field.
Description of Dependent and Independent Variables
The mean rate of change of VF MD over time for all eyes was −0.31 dB/y (SD: 0.71 dB/y) (Table 1, Fig. 1). Eyes with moderate or advanced glaucoma at baseline had a faster rate of VF MD loss over time compared with eyes with mild/suspect glaucoma (Table 2). On average, eyes with mild/suspect disease lost −0.28 dB/y [95% confidence interval (CI): −0.42 to −0.13], whereas eyes with moderate/advanced disease lost ∼−0.42 dB/y (95% CI: −0.60 to −0.24, P<0.01 comparing moderate/advanced disease to mild/suspect disease).
TABLE 2 -
The Effect of Treated IOP Metrics on VF Progression
|Disease Severity at Baseline
||MD Slope [Mean (95% CI)] (dB/y)
||Change in MD Slope for 1 mm Hg Increase in Mean Treated IOP When Mean IOP ≤21 (95% CI)
||Change in MD Slope for 1 mm Hg Increase in Mean Treated IOP When Mean IOP >21 (95% CI)
|Effect of mean treated IOP on VF progression
||−0.28 (−0.42 to −0.13)*
||−0.01 (−0.02 to 0.01)
||−0.09 (−0.14 to −0.03)*
||−0.42 (−0.60 to −0.24)*
||−0.02 (−0.04 to 0.00)*
||−0.74 (−0.88 to −0.60)*
|Disease Severity at Baseline
||MD Slope [Mean (95% CI)] (dB/y)
||Change in MD Slope for 1 mm Hg Increase in Maximum Treated IOP When Maximum IOP ≤31 (95% CI)
||Change in MD Slope for 1 mm Hg Increase in Maximum Treated IOP When Maximum IOP>31 (95% CI)
|Effect of maximum treated IOP on VF progression
||−0.29 (−0.44 to −0.14)*
||−0.01 (−0.02 to 0.00)
||−0.14 (−0.20 to −0.09)*
||−0.41 (−0.59 to −0.23)*
||−0.01 (−0.03 to 0.00)
||−0.26 (−0.33 to −0.20)*
|Disease Severity at Baseline
||MD Slope [Mean (95% CI)] (dB/y)
||Change in MD Slope for 1 mm Hg Increase in SD of Treated IOP When SD IOP ≤5 (95% CI)
||Change in MD Slope for 1 mm Hg Increase in SD of Treated IOP When SD IOP >5 (95% CI)
|Effect of SD of treated IOP on VF progression
||−0.29 (−0.44 to −0.14)*
||−0.03 (−0.07 to 0.01)
||−0.17 (−0.24 to −0.10)*
||−0.39 (−0.56 to −0.21)*
||−0.01 (−0.07 to 0.04)
||−0.22 (−0.30 to −0.15)*
CI indicates confidence interval; IOP, intraocular pressure; MD, mean deviation; VF, visual field.
Mean (14.3, SD: 3.5) and maximum treated IOP (18.7, SD: 5.1) of eyes with moderate/advanced disease tended to be lower than the mean (16.4, SD: 3.5) and maximum treated IOP (20.2, SD: 4.9) of eyes with mild/suspect disease (P<0.01 for both comparisons) (Fig. 2). The SD of treated IOP was slightly higher in eyes with moderate/advanced eyes compared with eyes with mild disease (2.9 vs. 2.7, respectively, P=0.01).
Influence of IOP on VF Change
The influence of mean IOP on change in VF MD varied by disease severity and overall level of treated IOP (Fig. 3, Table 2). After conducting a formal analysis for the ideal location spline knots,25 a single knot at 21 mm Hg was found to be the ideal location for a spline knot, and therefore we added a spline knot at this location. In addition, because the impact of treated IOP parameters on MD slope appeared to vary by disease severity at baseline (Fig. 3), we added interaction terms to the models to account for the varying effect of treated IOP on MD slope by disease severity.
Table 2 and Figure 3 (top) demonstrate that for mean IOPs <21 mm Hg, treated IOP appeared to not affect the rate of VF worsening in eyes with mild/suspect disease (−0.01 decrease in MD slope per 1 mm Hg increment in IOP, P=0.26). For eyes with moderate/advanced disease, at mean treated IOPs <21 mm Hg, a 1 mm Hg increment in mean treated IOP did result in a statistically significant higher rate of VF worsening (−0.02 dB/y per 1 mm Hg increment in IOP, P<0.05). Above a threshold of 21 mm Hg, both eyes with mild/suspect and moderate/advanced disease show higher rates of VF worsening with higher levels of mean treated IOP. However, the influence of a 1 mm Hg treated IOP increment was much more profound in eyes with moderate/advanced glaucoma compared with eyes with mild/suspect glaucoma (−0.74 dB/y for 1 mm Hg increment in mean treated IOP >21 mm Hg vs. −0.09 dB/y per 1 mm Hg increment in mean treated IOP, P<0.05 for both). Sixty-eight of 377 eyes with moderate/advanced disease (18.0%) with mean IOP values < 21 underwent rapid VF worsening (−1.0 dB/y or worse), compared with 54 of 952 (5.7%) eyes with mild/suspect disease (P<0.01 when comparing moderate/advanced eyes to mild/suspect eyes).
Based on the results of our models, we found that various levels of mean treated IOP over follow-up affected eyes with mild/suspect disease and moderate/advanced disease differently (Table 3). Our models estimate that, on average, it will take ∼3.2 years (95% CI: 2.9-4.0 y) for an eye with mild/suspect glaucoma and a mean IOP of 20 mm Hg over the follow-up to lose 1 dB of MD. Whereas for a treated eye with moderate/advanced glaucoma, it would only take 1.9 years (95% CI: 1.5-2.4 y) to achieve the same MD loss. At a mean treated IOP of 30, on average, an eye with mild/suspect disease would take 0.8 years (95% CI: 0.7-1.9 y) to experience 1 dB of VF loss, whereas a treated eye with advanced/moderate disease would achieve this same level of loss in just 0.1 years (95% CI: 0.1-0.2 y).
TABLE 3 -
Average Number of Years Required to Lose 1 dB of Mean Deviation at Various Mean Treated Intraocular Pressures (95% Confidence Interval)
|Disease Severity at Baseline
||10 mm Hg
||15 mm Hg
||20 mm Hg
||25 mm Hg
||30 mm Hg
The likelihood of experiencing a rate of VF MD worsening of at least −0.5 dB/y varied across the level of the mean (Fig. 4) treated IOP for eyes with mild/suspect versus moderate/advanced disease at baseline. Higher levels of mean treated IOP were associated with a higher likelihood of VF worsening in both mild/suspect and moderate/advanced disease (Table 4). In addition, we found that lower mean IOP was not associated with VF improvement (defined as MD slope >0) in adjusted regression models in both the mild/suspect group (odds ratio=0.99; 95% CI: 0.92-1.05) or the moderate/advanced group (odds ratio=0.95; 95% CI: 0.86-1.05).
TABLE 4 -
The Effect of Treated IOP Metrics on Likelihood of VF Worsening
|Disease Severity at Baseline
||Odds Ratio for 1 mm Hg Increase in Mean Treated IOP (95% CI)
|Effect of mean treated IOP on odds of VF loss of 0.5 dB/y
|Disease Severity at Baseline
||Odds Ratio for 1 mm Hg Increase in Maximum Treated IOP When Maximum IOP ≤33 (95% CI)
|Effect of maximum treated IOP on odds of VF loss of 0.5 dB/y
|Disease Severity at Baseline
||Odds Ratio for 1 mm Hg Increase in SD of Treated IOP When SD IOP ≤5 (95% CI)
|Effect of SD of treated IOP on odds of VF loss of 0.5 dB/y
CI indicates confidence interval; IOP, intraocular pressure; VF, visual field.
We attempted to adjust for the impact of outliers in our dataset. There were 4 eyes with an MD slope <−5.0 dB/y which may have unduly influenced the modeling results. In addition, there were 17 eyes with mean IOP values >25 mm Hg over follow-up. We separately removed these 2 sets of eyes from the analysis and found that there were no notable differences in the primary results stated above which reinforces the notion that higher mean treated IOP result in faster rates of VF MD loss and that the effects of IOP on VF loss varies by the absolute level of IOP and disease severity.
To account for the fact that some eyes included in the analysis were glaucoma suspects or ocular hypertensives and may not have the same risk of VF worsening as eyes with manifest glaucoma, we ran the models without these eyes. Again, our results showed no notable difference from the primary results stated above and in the tables and figures. In addition, to account for the fact that we merged eyes with moderate and advanced glaucoma into 1 subgroup for greater statistical power, we performed a sensitivity analysis which categorized eyes into 3 separate subgroups for mild, moderate, and advanced disease. We found that the main results of our work did not change except in the subgroup of eyes with advanced glaucoma with a mean IOP >21 mm Hg. There were very few eyes in this group (n=3), and unsurprisingly there was no significant relationship between mean IOP and VF worsening in this subset of eyes.
We attempted to account for eyes that may have had many clinical visits over a short period of time and therefore have a disproportionate influence on IOP metrics. For any eye with VF and clinical measurements < 6 months apart, we used mean IOP values of the visits within the 6-month time frame as input into our models. Again, the primary results of the models in this sensitivity analysis were not notably different from the primary results described in the tables and figures.
Our study demonstrates that, even among patients undergoing management at an academic center, higher mean treated IOP is associated with higher rates of VF loss and that the effects of mean treated IOP on VF loss vary by disease stage. In particular, eyes with moderate/advanced disease tend to progress at a faster rate at the same treated IOP levels compared with treated eyes with mild disease and tend to progress at mean treated IOP levels in the mid to high teens, unlike eyes with mild/suspect disease which, on average, do not progress with treated IOPs in this range. In addition, our work suggests that incremental differences in treated IOP have vastly different effects when occurring at different absolute levels of IOP. For instance, the impact of a 1 mm Hg mean treated IOP increment in an eye with a mean treated IOP in the 20s results in a much larger rate of VF loss than in an eye with a mean treated IOP in the teens, suggesting that the impact of IOP is nonlinear across the range of IOP.
Our results suggest that glaucoma stage at baseline is an important modifier of the effect of IOP measures on VF worsening, even in treated eyes. In particular eyes with the advanced disease tend to progress more at the same levels of mean, maximum, and SD treated IOP (Table 2, Figs. 3, 4). These findings are in agreement with prior work which has demonstrated that the diagnosis of advanced glaucoma at baseline is associated with a higher risk of VF loss over follow-up despite treatment.6,27–29 Furthermore, our data suggest that the baseline rate of VF loss is higher in treated eyes with moderate/advanced disease compared with mild disease at baseline (Table 2), despite the fact that these eyes were treated more aggressively (with lower treated IOPs). Our study also demonstrates that increments in IOPs tend to have more significant impacts on the rate of VF loss in treated eyes with moderate/advanced glaucoma at baseline compared with eyes with mild/suspect disease. Specifically, treated eyes with moderate/advanced disease tended to deteriorate faster with higher IOP even over the lower IOP range, unlike treated eyes with mild disease, which showed no significant difference in the rate of deterioration over these lower treated IOP levels. These results suggest that when physicians follow recommendations that IOP should be kept in the mid-teens or lower in eyes with moderate/advanced disease5,30,31 and low 20s or lower in eyes with mild/suspect disease,2,32–34 VF progression is minimal.
As IOPs were treated, our data do not indicate ideal treatment guidelines but rather indicate when treatment failure is most likely. Given that worsening occurred even in the lower IOP range in advanced glaucoma patients, even though these individuals are likely to be more visually impaired and have less functional reserve, one could argue that treatment of this group could have been more aggressive. However, additional IOP lowering in this group needs to be balanced against the risk of treatment (particularly for surgical therapy) or the burden of therapy. Moreover, worsening may be harder to detect in this group given the greater variability in VF testing in advanced disease.24,35
Our work also demonstrates that the absolute level of treated IOP modifies the effect of changes in IOP on VF worsening, even in clinical populations where physicians are setting IOP goals to minimize disease worsening. In particular, in eyes with moderate/advanced disease, higher IOP over the lower range of IOP tended to have a small, albeit statistically significant impact on the speed of VF worsening, whereas at higher IOP ranges (>20 mm Hg), the effect of equivalent increments in IOP on VF worsening is particularly worse. While prior work has demonstrated that the risk of VF worsening decreases by 10% to 20% per mm Hg reduction in IOP,1,12,36,37 prior studies have not generally focused on whether the effect of IOP on glaucoma worsening depends on the absolute level of IOP. This is an important distinction for clinicians who treat glaucoma patients, as interventions that reduce the IOP from the mid-20s to the mid to high teens are likely to have a more substantial impact at slowing the rate of VF loss compared with interventions that lower patients IOP from the mid-teens to the low teens or single digits. Often, the later interventions including traditional filtering surgeries such as trabeculectomy which are often associated with high rates of complications.19 In addition, though some work has found that lower IOP levels are associated with VF improvement,38 logistic regression modeling with our dataset did not demonstrate that lower mean IOP was associated with VF improvement (MD slope >0). We hypothesize that much of the VF improvement in this study was due to VF learning effect39 which is likely independent of IOP.
We also found that higher maximum IOP and SD of treated IOP measurements are associated with greater rates of VF loss in both eyes with mild and moderate/advanced damage. In particular, when maximum treated IOP values were in the 30s, they were associated with significant VF worsening. These data confirm the findings of AGIS5 as well as other groups,40 which demonstrate that even peak IOP levels (>18 mm Hg in AGIS) are associated with higher rates of worsening. Our results differ from these studies as we used splines terms to determine if maximum treatment IOP had different effects over the range of observed treatment IOPs. As such, our results cannot be directly compared with these prior studies. Based on these results, it is important for clinicians managing glaucoma patients to note that even the occasional spike of IOP into the 30s suggests rapid future worsening, and likely the need for more aggressive IOP lowering. Our work also agrees with prior work suggesting that higher inter-visit fluctuation in IOP (as measured by higher SD IOP) is associated with faster rates of VF loss.3,10 However, unlike prior work, our study demonstrates this effect is significant only when the SD of treated IOP is >5 mm Hg both for mild disease and moderate/advanced disease. These results indicate that while IOP fluctuations may play a role in glaucoma worsening, the rates of occurrence of levels of fluctuation that influence worsening are relatively low in a treated clinical population. Moreover, such measures are of lower practical significance, given the difficulty in calculating SD IOP in clinical practice. Finally, in the setting of treatment, variability in treated IOP may reflect changes in management due to progression (ie, a surgical procedure such as trabeculectomy that dramatically lowers IOP but increases SD IOP), as opposed to a cause of progression.
Our data provide valuable insight regarding how long it takes certain levels of IOP to produce damage to visual function in various subsets of treated glaucoma patients. Based on the results presented in Table 3, at a treated IOP of 25, on average eyes with mild disease will take 1.5 years to lose 1 dB of VF, whereas for an eye with advanced disease, the time it takes to lose a similar amount of field is 0.3 years. However, it must be noted that the course of each patients VF worsening is unique as demonstrated by the variation in the rates of VF loss and the likelihood of worsening at various levels of IOP in Figures 3 and 4, respectively, therefore it is of paramount importance that the clinician follows each patients course individually with serial glaucoma testing as recommended by current guidelines41 before making concrete treatment decisions. However, the results of this work suggest when treatment is likely to be successful for patients treated in glaucoma clinics:
- For patients with the mild or suspect disease, when IOP < 20 mm Hg is achieved, progressive VF loss was minimal and uncommon. This suggests that physicians (at least in this group) are sufficiently aggressive when achieving IOP lowering over this IOP range.
- For moderate/advanced disease, lower treatment IOPs even in the < 20 mm Hg range is associated with slower VF loss, although the relative impact of IOP decrements in this range likely is less than the impact of IOP decrements over the higher range of IOP (the 20s and above).
- Treated IOPs in the 30s at any stage of disease indicates a poor clinical course. Patients with IOPs in this range despite being followed may have had unique reasons for not undergoing further therapy (aversion to surgery, poor compliance or medication tolerance, high surgical risk) and should be counseled about the high likelihood and rate of vision loss.
There are several limitations to the work presented here. First, we have used VF worsening as our primary outcome measure as our database did not include any structural data from OCT and may miss worsening that is occurring structurally but not functionally. In addition, due to the lower prevalence of moderate and advanced disease in our population, we were unable to separate these 2 groups due to a lack of statistical power. Future work with a larger dataset including both structural parameters and more eyes may allow us to address these issues. Finally, these results should only be applied to a treated clinical population, they are likely not generalizable to an untreated group of patients (ie, studies of new glaucoma patients, community-based glaucoma screenings, etc.). In untreated patients with glaucoma and baseline IOPs in the high 20s, some prior work has shown that an IOP lowering of 20% to 30% from pretreatment levels results in no visual field loss at 5 years of follow-up.42 However, when compared with other studies that assessed newly diagnosed glaucoma patients, the results of our logistic modeling, which suggest that there is a 9 to 13% higher likelihood of VF worsening for every mm Hg increment in IOP are consistent with the previously demonstrated results from EMGT.32 However, it should be noted that EMGT defined worsening with pointwise criteria and optic nerve photos unlike our definition of worsening which depended on MD slope <0.5 dB/y, so these similar numbers may have been coincidental.
In summary, our data demonstrate that, in treated eyes, glaucoma worsening related to IOP is dependent on the stage of glaucoma as well as the treated IOP range. On average, eyes with advanced disease and/or a higher treated IOP range tend to have more VF loss with further treated IOP increments compared with eyes with less advanced disease and/or lower treated IOP range.
1. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–720; discussion 829–830.
2. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713; discussion 829–830.
3. Musch DC, Gillespie BW, Niziol LM, et al. CIGTS Study Group. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2011;118:1766–1773.
4. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393:1505–1516.
5. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000;130:429–440.
6. Mikelberg FS, Schulzer M, Drance SM, et al. The rate of progression of scotomas in glaucoma. Am J Ophthalmol. 1986;101:1–6.
7. Lazaro C, Garcia-Feijoo J, Castillo A, et al. Impact of intraocular pressure after filtration surgery on visual field progression in primary open-angle glaucoma. Eur J Ophthalmol. 2007;17:357–362.
8. Oie S, Ishida K, Yamamoto T. Impact of intraocular pressure reduction on visual field progression in normal-tension glaucoma followed up over 15 years. Jpn J Ophthalmol. 2017;61:314–323.
9. Iverson SM, Schultz SK, Shi W, et al. Effectiveness of single-digit iop targets on decreasing global and localized visual field progression after filtration surgery in eyes with progressive normal-tension glaucoma. J Glaucoma. 2016;25:408–414.
10. Rao HL, Addepalli UK, Jonnadula GB, et al. Relationship between intraocular pressure and rate of visual field progression in treated glaucoma. J Glaucoma. 2013;22:719–724.
11. Hong S, Kim CY, Seong GJ. Long-term intraocular pressure fluctuation and visual field progression in glaucoma patients with low intraocular pressure after post-trabeculectomy phacoemulsification. J Ocul Pharmacol Ther. 2007;23:571–576.
12. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48–56.
13. McAlinden C. Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review. Eye. 2014;28:249–258.
14. Guedes RAP, Gravina DM, Lake JC, et al. One-year comparative evaluation of istent or istent inject implantation combined with cataract surgery in a single center. Adv Ther. 2019;36:2797–2810.
15. Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON Study. Ophthalmology. 2019;126:29–37.
16. Ahmed IIK, Fea A, Au L, et al. A prospective randomized trial comparing Hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: the COMPARE Study. Ophthalmology. 2019;127:52–61.
17. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153:789.e2–803.e2.
18. Budenz DL, Barton K, Gedde SJ, et al. Five-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology. 2015;122:308–316.
19. Gedde SJ, Herndon LW, Brandt JD, et al. Postoperative complications in the Tube Versus Trabeculectomy (TVT) Study during five years of follow-up. Am J Ophthalmol. 2012;153:804.e1–814.e1.
20. Clement CI, Bhartiya S, Shaarawy T. New perspectives on target intraocular pressure. Surv Ophthalmol. 2014;59:615–626.
21. Richler M, Werner EB, Thomas D. Risk factors for progression of visual field defects in medically treated patients with glaucoma. Can J Ophthalmol. 1982;17:245–248.
22. Araie M, Sekine M, Suzuki Y, et al. Factors contributing to the progression of visual field damage in eyes with normal tension glaucoma. Ophthalmology. 1994;101:1440–1444.
23. Stewart WC, Kolker AE, Sharpe ED, et al. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am J Ophthalmol. 2000;130:274–279.
24. Yohannan J, Wang J, Brown J, et al. Evidence-based criteria for assessment of visual field reliability. Ophthalmology. 2017;124:1612–1620.
25. Muggeo VMR. Estimating regression models with unknown break-points. Stat Med. 2003;22:3055–3071.
26. Chauhan BC, Malik R, Shuba LM, et al. Rates of glaucomatous visual field change in a large clinical population. Invest Ophthalmol Vis Sci. 2014;55:4135–4143.
27. Hyung SM, Youn DH. Visual prognosis in advanced glaucoma. Korean J Ophthalmol. 1989;3:22–27.
28. Wilson R, Walker AM, Dueker DK, et al. Risk factors for rate of progression of glaucomatous visual field loss: a computer-based analysis. Arch Ophthalmol. 1982;100:737–741.
29. Lee JM, Caprioli J, Nouri-Mahdavi K, et al. Baseline prognostic factors predict rapid visual field deterioration in glaucoma. Invest Ophthalmol Vis Sci. 2014;55:2228–2236.
30. [No authors listed]. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–497.
31. Odberg T. Visual field prognosis in advanced glaucoma. Acta Ophthalmol (Copenh). 1987;65(suppl 182):27–29.
32. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279.
33. Feiner L, Piltz-Seymour JR. Collaborative Initial Glaucoma Treatment Study. Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol. 2003;14:106–111.
34. Miglior S, Zeyen T, Pfeiffer N, et al. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005;112:366–375.
35. Aboobakar I, Wang J, Chauhan B, et al. Factors predicting a greater likelihood of poor visual field reliability in glaucoma patients and suspects. Transl Vis Sci Technol. 2020;9:4.
36. European Glaucoma Prevention Study (EGPS) Group, Miglior S, Pfeiffer N, Torri V, et al. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology. 2007;114:3–9.
37. Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126:1030–1036.
38. Musch DC, Gillespie BW, Palmberg PF, et al. Visual field improvement in the collaborative initial glaucoma treatment study. Am J Ophthalmol. 2014;158:96.e2–104.e2.
39. Heijl A, Bengtsson B. The effect of perimetric experience in patients with glaucoma. Arch Ophthalmol. 1996;114:19–22.
40. De Moraes CGV, Juthani VJ, Liebmann JM, et al. Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol. 2011;129:562–568.
41. Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert Committee, Canadian Ophthalmological Society. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol. 2009;44(suppl 1):S7–S93.
42. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–1953.